Related Experiment Video
Updated: Jul 13, 2026
09:11
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
[Nesiritide, a novel treatment for heart failure]
1Clínica de Insuficiencia Cardiaca, Unidad Médica de Alta Especialidad, Hospital de Especialidades 14, Veracruz, Veracruz, Instituto Mexicano del Seguro Social. g.mendez@imperial.ac.uk
Revista Medica Del Instituto Mexicano Del Seguro Social
|August 19, 2007
Summary
Nesiritide, a recombinant human-B-type natriuretic peptide (hBNP), effectively treats acute decompensated heart failure by improving cardiac index and reducing pulmonary capillary wedge pressure. Recent meta-analyses confirm no increased mortality risk with its use.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Acute decompensated heart failure (ADHF) presents significant clinical challenges.
- Current therapies aim to improve hemodynamics and reduce symptoms.
Purpose:
- To evaluate the efficacy and safety of Nesiritide in ADHF patients.
- To assess Nesiritide's impact on hemodynamic parameters and clinical outcomes.
Summary:
- Nesiritide, a recombinant human-B-type natriuretic peptide (hBNP), induces balanced arterial and venous dilation, reducing pulmonary capillary wedge pressure (PCWP) and increasing cardiac index.
- Treatment demonstrates rapid improvement in dyspnea, reduced ventricular tachyarrhythmia compared to dobutamine, and better tolerance than nitroglycerin.
- Clinical trials and meta-analyses indicate no increased short-term or long-term mortality risk.
Impact:
- Nesiritide offers a novel therapeutic option for ADHF.
- It provides hemodynamic benefits and symptom relief with a favorable safety profile.
- Evidence supports its role in managing acute heart failure exacerbations.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...